Regeneron aims for intracellular targets via Alnylam deal

Via an RNAi deal with Alnylam covering ocular and CNS diseases as well as certain targets in the liver, Regeneron is aiming to reach intracellular targets, complementing its experience in antibodies and cell-surface targets. The deal comes as Alnylam and Sanofi ended the research and option phase of their 2014 deal.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) will pay Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) $400 million up front and invest $400 million in the RNAi company's equity via the purchase of 4.4 million shares at $90. The purchase price is a 3% discount to Alnylam's close of $92.79 on Friday, before the deal was announced; Alnylam slipped $2.62 to $90.17 on Monday...